ELND005 Long-Term Follow-up Study in Subjects With Alzheimer's Disease
Status:
Completed
Trial end date:
2011-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the long-term safety and tolerability of ELND005
beyond the 18 months of treatment in original randomized and blinded clinical trail
ELND005-AD201.
Phase:
Phase 2
Details
Lead Sponsor:
OPKO Health, Inc. Transition Therapeutics Ireland Limited